APOA5 and metabolic dysfunction-associated steatotic liver disease: As a key regulatory enzyme at the last stage of hepatic de novo lipogenesis, enhanced hepatic SCD1 activity promotes the accumulation of hepatic lipids, consequently leading to the progression of fatty liver.20 FABP5 contributes to the development of diet‐induced obesity.21 PLIN2 is involved in the elevation of circulating free fatty acid concentrations.22 APOA5 is a liver‐specific protein that promotes hepatic TG storage and contributes to the pathogenesis of NAFLD.23 In our study, YZH liquid could suppress the expression of these lipogenic genes.